IDEXX Laboratories, Inc. (NASDAQ: IDXX), a leading pet healthcare company, on Monday reported an increase in revenue and net income for the second quarter of fiscal 2025.
- Second-quarter revenue increased to $1.11 billion from $1.0 billion in the prior-year quarter, up 11%
- On an organic basis, revenue grew 9%, supported by CAG diagnostics recurring revenue growth of 9% as reported and 7% organic
- Net income was $294.0 million in Q2 2025, compared to $203.3 million in the prior-year quarter
- Earnings, on a per-share basis, climbed 49% year-over-year to $3.63 in Q2; EPS grew 17% on a comparable basis
- The management raised its full-year revenue guidance to $4,205-4,280 million, an increase of $90 million or around 2% at midpoint
- The guidance for full-year reported revenue growth is 7.7-9.7%; CAG diagnostics recurring revenue growth is expected to be 6.5-8.7%
- It expects full-year earnings to be in the range of $12.40 per share to $12.76 per share
Listen to the conference calls as they happen. Don't miss a beat! With AlphaStreet Intelligence, you can listen to live calls and interviews as they happen, so you never have to worry about missing out on important information.
Most Popular
Infographic: How Constellation Brands (STZ) performed in Q3 2026
Constellation Brands, Inc. (NYSE: STZ) reported net sales of $2.22 billion for the third quarter of 2026, down 10% year-over-year. Organic net sales were down 2%. Net income attributable to
BLK Q4 Preview: BlackRock appears poised for another earnings beat
BlackRock, Inc. (NYSE: BLK), the largest asset management company, is expected to publish its fourth-quarter 2025 results next week. The update is expected to shed light on how the firm’s
A look at Best Buy’s (BBY) progress on its growth strategy
Shares of Best Buy Co., Inc. (NYSE: BBY) fell over 3% on Wednesday. The stock has dropped 17% over the past 12 months. The consumer electronics retailer delivered sales and
